Attorney's Docket No.: 14503-010US1 / F62904PCUS HJW/hor



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Michele Orlando et al.

Art Unit: 1623

10/506,366

Examiner: Everett NMN White

Filed

: February 2, 2005

Conf. No.: 1083

Title

: COUPLING LOW-MOLECULAR SUBSTANCES TO A MODIFIED

POLYSACCHARIDE

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL

The following correspondence relating to this application is enclosed for filing:

- Supplemental Information Disclosure Statement (1 page); 1.
- 2. Form PTO-1449 (15 pages);
- Copies of Cited References (287 references); and 3.
- A Return Postcard. 4.

Please date stamp and return the enclosed postcard. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: Mumber 27

Elizabeth N. Kaytor, Ph.D. Reg. No. 53,103

Fish & Richardson P.C. 60 South Sixth Street, Suite 3300 Minneapolis, MN 55402 (612) 335-5070 telephone (612) 288-9696 facsimile

60401905.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

•			
Date of Deposit			
Signature			
	Lisa M. Becker		
Typed or Printed N	ame of Person Signing Certificate		



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michele Orlando et al.

Art Unit : 1623

Serial No.: 10/506,366

Examiner: Everett NMN White

Filed

: February 2, 2005

Conf. No.: 1083

Title

: COUPLING LOW-MOLECULAR SUBSTANCES TO A MODIFIED POLYSACCHARIDE

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: Number 27, 2006

<u>Elizabeth N. Kaytor, Ph.D.</u>

Reg. No. 53,103

Fish & Richardson P.C. 60 South Sixth Street, Suite 3300

Minneapolis, MN 55402 Telephone: (612) 335-5070 Facsimile: (612) 288-9696

60401896.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	December 28 , 2006
Date of Deposit	Marine
Signature	
	Lisa M. Becker

Typed or Printed Name of Person Signing Certificate

Modified Pro-1449 3 100 Information Disclosure Statement

U.S. Department of Commerce Patent and Trademark Office

by Applicant

Attorney's Docket No. 14503-010US1

Application No. 10/506,366

Applicant

Michele Orlando et al.

Filing Date

Group Art Unit 1623

(Use several sheets if necessary) February 2, 2005

U.S. Patent Documents Filing Date Examiner Desig. Document Publication Date Patentee Class Subclass If Appropriate Initial Number ID 06/29/65 Maier 1 3,191,291 Wong 2 12/20/77 4,064,118 11/14/78 Cuatrecasas et al. 3 4,125,492 12/18/79 Davis et al. 4 4,179,337 5 04/14/81 Lee et al. 4,261,973 11/01/83 4,412,989 Iwashita et al. 6 7 . 4,667,016 05/19/87 Lai et al. 10/27/87 Lin 8 4,703,008 Katre et al. 9 4,766,106 08/23/88 07/11/89 Shadle et al. 10 4,847,325 09/05/89 Hedlund et al. 11 4,863,964 02/27/90 Shaw 4,904,584 12 11/26/91 Buysch et al. 13 5,068,321 14 05/25/93 Kuga et al. 5,214,132 Hedlund et al. 15 5,217,998 06/08/93 Sasaki et al. 06/08/93 5,218,092 16 06/08/93 Sommermeyer et al. 5,218,108 17 01/25/94 Nitecki 18 5,281,698 11/08/94 Kuga et al. 19 5,362,853 11/28/95 Stahl et al. 5,470,843 20 5,484,903 01/16/96 Szablikowski et al. 21 Lihme et al. 22 5,543,332 08/06/96 Osslund 23 5,581,476 12/03/96 Al-Shamkhani et al. 04/22/97 24 5,622,718 07/04/00 Sommermeyer et al. 6,083,909 25 04/29/03 Nissen et al. 26 6,555,660 09/16/04 Sommermeyer 27 2004/0180858

Examine	er Sigr	nature
---------	---------	--------

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-010US1	Application No. 10/506,366
	closure Statement	Applicant Michele Orlando et al	l.
	heets if necessary)	Filing Date February 2, 2005	Group Art Unit 1623

	Foreig	n Patent Doc		ublished Foreign I	Patent A	Application		
Examiner	Desig.	Document	Publication	Country or	Closs	Cubalasa		lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	28	2 441 442	09/26/03	CA				
	29	2 478 478	01/09/04	CA .		· 		
	30	2 478 480	01/09/04	CA				
	31	279 486	06/06/90	DD			Abst.	
	32	100 41 541	03/14/02	DE			Abst.	
	33	101 12 825	02/10/02	DE			Abst.	
	. 34	101 26 158	12/12/02	DE			Abst.	
	35	101 29 369	03/06/03	DE			Abst.	
	36	101 35 694	02/06/03	DE			Abst.	
	37	101 55 098	05/22/03	DE			Abst.	
	38	102 09 821	09/25/03	DE			Abst.	
	39	102 17 994	11/06/03	DE			Abst.	
	40	102 54 745	06/03/04	DE			Abst.	
	41	102 56 558	09/16/04	DE			Abst.	
	42	196 28 705	01/15/98	DE			Abst.	
	43	198 08 079	08/26/99	DE			Abst.	
	44	22 33 977	02/01/73	DE			Abst.	
	45	26 07 706	05/13/93	DE			Abst.	
	46	26 16 086	11/03/77	DE			Abst.	
	47	26 46 854	05/03/89	DE			Abst.	
	48	30 29 307	03/04/82	DE		"	Abst.	
	49	38 36 600	05/03/90	DE			Abst.	
	50	41 30 807	03/18/93	DE			Abst.	
-	51	0 019 403	11/26/80	EP				
	52	0 138 572	04/24/85	EP				
•	53	0 148 605	07/25/90	EP				
	54	0 205 564	05/02/91	ЕР				

Examiner Signature	Date Considered
	if not in conformance and not considered leading comy of this form with

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 14503-010US1

Application No. 10/506,366

Information Disclosure Statement by Applicant (Use several sheets if necessary) Applicant
Michele Orlando et al.

Filing Date

Group Art Unit

(37 CFR §1.98(b))

February 2, 2005

1623

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or Patent Office	Class	Subclass	Trans Yes	lation No
Initial	ID	Number	Date	EP Faterit Office	Class	Subciass	165	INO
	55	0 243 929	11/04/87					
	56	0 304 183	02/22/89	EP				
	57	0 307 827	03/22/89	EP				
	58	0 315 349	05/10/89	EP				
	59	0 338 916	10/25/89	EP			Abst.	
	60	0 402 724	06/02/90	EP			Abst.	
	61	0 411 678	01/08/92	EP				
<u> </u>	62	0 418 523	06/21/95	EP				
	63	0 428 267	05/22/91	EP				
	64	0 605 963	07/13/94	EP				
	65	0 609 968	08/10/94	EP				
	66	0 640 619	03/01/95	EP				
	67	0 646 130	04/05/95	EP				
	68	0 668 351	08/23/95	EP				
	69	0 809 996	05/31/96	EP		- 1		
	70	1 230 935	08/14/02	EP			Abst.	
	71	1 398 322	09/11/03	EP				
	72	1 398 327	09/11/03	EP				
	73	1 398 328	09/11/03	EP				
	74	1 400 533	09/11/02	EP				
	75	1 419 080	12/24/75	GB				
	76	WO 02/80979	10/17/02	WIPO			Abst.	
	77	WO 02/09766	02/07/02	WIPO				
·	78	WO 02/40057	05/23/02	WIPO				
	79	WO 03/00738	01/03/03	WIPO			Abst.	
•	80	WO 03/59246	07/24/03	WIPO				
	81	WO 03/74087	09/12/03	WIPO			Abst.	

_	-	0: 1
	Examiner	Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 14503-010US1

Application No. 10/506,366

Information Disclosure Statement by Applicant (Use several sheets if necessary) Applicant
Michele Orlando et al.

Filing Date

Group Art Unit

(37 CFR §1.98(b))

February 2, 2005 1623

	Foreig	n Patent Doc		ublished Foreign l	Patent A	Application	ns	
Examiner	Desig.	Document	Publication	Country or	<u> </u>			lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
120	82	WO 03/74088	09/12/03	WIPO			Abst.	
	83	WO 04/09082	01/29/04	WIPO				
	84	WO 04/24761	03/25/04	WIPO ·				
	85	WO 04/50710	06/17/04	WIPO			Abst.	
	86	WO 04/65425	08/05/04	WIPO			Abst.	
	87	WO 90/07939	07/26/90	WIPO				
	88	WO 90/15628	12/27/90	WIPO				
	89	WO 93/23062	11/25/93	WIPO				
	90	WO 94/01483	01/20/94	WIPO				
	91	WO 94/13697	06/23/94	WIPO				
	92	WO 94/28024	12/08/94	WIPO				
	93	WO 94/29370	12/22/94	WIPO				
*	94	WO 95/06058	03/02/95	WIPO				
	95	·WO 95/13090	05/18/95	WIPO				
	96	WO 96/11953	04/25/96	WIPO				
	97	WO 96/19242	06/27/96	WIPO				
	98	WO 96/40662	12/19/96	WIPO				
	99	WO 96/41813	12/27/96	WIPO				
	100	WO 97/21452	06/19/97	WIPO				
	101	WO 97/30148	08/21/97	WIPO				
	102	WO 97/33552	09/18/97	WIPO				
	103	WO 97/38727	10/23/97	WIPO			Abst.	
<u> </u>	104	WO 98/01158	01/15/98	WIPO			Abst.	
•	105	WO 98/08856	03/05/98	WIPO			Abst.	
_	106	WO 98/20905	05/22/98	WIPO				
•	107	WO 98/32466	07/30/98	WIPO			Abst.	
	108	WO 98/56424	12/17/98	WIPO				

Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-010US1	Application No. 10/506,366	<u>_</u> _
	closure Statement	Applicant Michele Orlando et al	•	
	eets if necessary)	Filing Date February 2, 2005	Group Art Unit 1623	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
	109	WO 99/49897	10/07/99	WIPO				

(Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document			
	110	Abuchowski and Davis, "Soluble Polymer-Enzyme Adducts," Enzymes as Drugs, 1981, Holcenberg and Rubberts (eds.), Chapter 13, pp. 367-383, John Wiley & Sons N.Y.			
	111	Alayash and Cashon, "Hemoglobin and free radicals: implications for the development of a safe blood substitute," Molec. Med. Today, 1995, 1(3):122-127			
	112	Ashwell, "Carbohydrate Antigens: Coupling of Carbohydrates to Proteins by a Mixed Anhydride Reaction," Meth. Enzymol., 1972, 28:219-222			
	113	Avigad, "A Simple Spectrophotometric Determination of Formaldehyde and Other Aldehydes: Application to Periodate-Oxidized Glycol Systems," Anal. Biochem., 1983, 134:499-504			
	114	Baldwin et al., "Synthesis of Polymer-Bound Hemoglobin Samples," <u>Tetrahedron</u> , 1981, 37:1723-1726			
	115	Balland et al., "Intracellular distribution of ampicillin in murine macrophages infected with Salmonella typhimurium and treated with (³ H)ampicillin-loaded nanoparticles," <u>J. Antimicrob.</u> Chemother., 1996, 37:105-115			
	116	Anal., 1994, 12(4):515-522			
	117	Bårström et al., "New derivatives of reducing oligosaccharides and their use in enzymatic reactions: efficient synthesis of sialyl Lewis a and sialyl dimeric Lewis x glycoconjugates," <u>Carbohydr. Res.</u> , 2000, 328:525-531			
	118				
	119	Bauer and Suresh, "S-[w-(Aminoöxy)alkyl]isothiuronium Salts, w,w'-Bis(aminoöxy)alkanes and Related Compounds," J. Org. Chem., 1963, 28:1604-1608			
	120	Bendele et al., "Short Communication: Renal Tubular Vacuolation in Animals Treated with Polyethylene-Glycol-Conjugated Proteins," <u>Toxicol. Sci.</u> , 1998, 42:152-157			
	121	Benesch, "Bis(pyridoxal) Polyphosphates as Specific Intramolecular Cross-Linking Agents for Hemoglobin," Meth. Enzymol., 1994, 231:267-274			
	122	Bepperling et al., "HES 130/0.4, a new HES specification: tissue storage after multiple infusions in rats." Crit. Care, 1999, 3(suppl 1):P153			
	123	Berger et al., "Galactosyltransferase-dependent sialylation of complex and endo-N-acetylglucosaminidase H-treated core N-glycans in vitro," FEBS Lett., 1986, 203(1):64-68			
	124	Black et al., "N-Bromoacetyl-glycopyranosylamines as affinity labels for a β-glucosidase and a cellulase," Carbohydr. Res., 1993, 250:195-202			
	125				
•	126	tertiary structure, J. Biol. Chem., 1993, 200(21):13983-13993			
	127	Boturyn et al., "Synthesis of Fluorescent Probes for the Detection of Abasic Sites in DNA," <u>Tetrahedron</u> , 1997, 53(15):5485-5492			

Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with				
next communication to applicant.	Substitute Disclosure Form (PTO-1449)			

Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 14503-010US1	Application No 10/506,366
	closure Statement	Applicant Michele Orlando et al.	
(Use several sheets if necessary) (37 CFR \$1.98(b))		Filing Date February 2, 2005	Group Art Unit 1623

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document			
	128	Bowen et al., "Estimation of Effective and Total Erythropoiesis in Myelodysplasia Using Serum Transferrin Receptor and Erythropoietin Concentrations, with Automated Reticulocyte Parameters," Leukemia, 1994, 8(1):151-155			
	129	Bronzino, The Biomedical Engineering Handbook, CRC Press, USA, Salem, 1995, (TOC only)			
	130	Bunn & Jandl, "The Renal Handling of Hemoglobin. II. Catabolism," J. Exp. Med., 1967, 129:925-934			
	131	Burgess et al., "Stimulation by Human Placental Conditioned Medium of Hemopoietic Colony Formation by Human Marrow Cells," <u>Blood</u> , 1977, 49(4):573-583			
	132	Bystrický et al., "Determination of the cross-linking effect of adipic acid dihydrazide on glycoconjugate preparation," Glycoconj. J., 1999, 16:691-695			
	133	Cabacungan et al., "Amine Boranes as Alternative Reducing Agents for Reductive Alkylation of Proteins," Anal. Biochem., 1982, 124:272-278			
	134	Carlsson et al., "Protein Thiolation and Reversible Protein-Protein Conjugation," <u>Biochem J.</u> , 1978, 173:723-737			
	135	Cerami, "Beyond Erythropoiesis: Novel Applications for Recombinant Human Erythropoietin," Semin. Hematol., 2001, 38:(3 Suppl 7):33-39			
	136	Cerny et al., "A Hydroxyethyl Starch-Hemoglobin Polymer as a Blood Substitute," Clinical Hemorheology, 1982, 2(4):355-365			
	137	Chamow et al., "Conjugation of Soluble CD4 without Loss of Biological Activity via a Novel Carbohydrate-directed Cross-linking Reagent," J. Biol. Chem., 1992, 267(22):15916-15922			
	138	Chang, "Blood Substitutes Based on Modified Hemoglobin Prepared by Encapsulation or Crosslinking: An Overview," <u>Biomat., Art. Cells & Immob. Biotech.</u> , 1992, 20:159-179			
	139	Chagnon et al., "Murine renal cell carcinoma: evaluation of a dendritic-cell tumour vaccine," <u>BJU</u> <u>Int.</u> , 2001, 88:418-424			
	140	Chaplin, "Monosaccharides," <u>Carbohydrate analysis: a practical approach</u> , 1996, Chaplin and Kennedy (eds.), Chapter 1, "Oligosaccharides," pp. 37-54			
	141	Chaplin, "A Rapid and Sensitive Method for the Analysis of Carbohydrate Components in Glycoproteins Using Gas-Liquid Chromatography," Anal. Biochem., 1982, 123:336-341			
	142	Biotecn., 1999, 17:780-783			
	143	2001, 86:485-493			
	144	Chu et al., "Further Studies on the Immunogenicity of <i>Haemophilus influenzae</i> Type b and Pneumococcal Type 6A Polysaccharide-Protein Conjugates," <u>Infect. Immun.</u> , 1983, 40:245-256			
	145	Cumber et al., "Preparation of Antibody-Toxin Conjugates," Meth. Enzymol., 1985, 112:207-225			
	146	Syst., 1992, 9(3,4):249-304			
•	147	Delorme et al., "Role of Glycosylation on the Secretion and Biological Activity of Erythropoietin," Biochemistry, 1992, 31(41):9871-9876			
	148	Dittmar et al., "Human Glycoproteins and Derived Variants from Recombinant Mammalian Cell Lines," <u>Advances in Protein Design</u> , 1989, 12:145-156			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with
The second of th	Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 14503-010US1	Application No. 10/506,366
	closure Statement pplicant	Applicant Michele Orlando et al.	
(Use several s	heets if necessary)	Filing Date	Group Art Unit
(37 CFR §1.98(b))		February 2, 2005	1623

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.	Danish			
Initial	ID	Document			
	149	Dorner et al., "Increased Synthesis of Secreted Proteins Induces Expression of Glucose-regulated Proteins in Butyrate-treated Chinese Hamster Ovary Cells," J. Biol. Chem., 1989, 264(34):20602-20607			
	150	Dowling and Russell, "Pharmacokinetics of a long-acting oxytetracycline-polyethylene glycol formulation in horses," J. Vet. Pharmacol. Therap., 2000, 23:107-110			
,	151	Dreborg and Åkerblom, "Immunotherapy with Monomethoxypolyethylene Glycol Modified Allergens," Crit. Rev. Ther. Drug Carrier Syst., 1990, 6(4):315-365			
	152	Edmunds et al., "Transgenically Produced Human Antithrombin: Structural and Functional Comparison to Human Plasma-Derived Antithrombin," <u>Blood</u> , 1998, 91(12):4561-4571			
	153	Blum et al., "Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels," Electrophoresis, 1987, 8:93-99			
	154	Elliott et al., "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 1997, 89(2): 493-502			
	155	European Pharmacopoeia, "Erythropoietin Concentrated Solution," 3rd Edition, 2000, Monography, pp. 655-660			
	156	European Pharmacopoeia, "Erythropoietin Concentrated Solution," 4th Edition, 2002, Monography, pps. 1123-1128			
	157	Fernández-Santana et al., "Conjugation of 5-azido-3-oxapentyl glycosides with thiolated proteins through the use of thiophilic derivatives," <u>Glycoconj. J.</u> , 1998, 15:549-553			
	158	Fibi et al., "Evidence for the Location of the Receptor-Binding Site of Human Erythropoietin at the Carboxyl-Terminal Domain," <u>Blood</u> , 1991, 77(6):1203-1210			
	159	Fibi et al., "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," Blood, 1995, 85(5):1229-1236			
`	160	Fissekis et al., "N-Pantyol-(substituted)amines, Pantothenic Acid Analogues," J. Med. Pharm. Chem., 1960, 2:47-56			
	161	line," Eur. J. Biochem., 2004, 271:907-919			
	162	Gaertner and Offord, "Site-Specific Attachment of Functionalized Poly(ethylene glycol) to the Amino Terminus of Proteins," <u>Bioconjugate Chemistry</u> , 1996, 7(1):38-44			
	163	Gervais et al., "NMR investigations of the role of the sugar moiety in glycosylated recombinant human granulocyte-colony-stimulating factor," <u>Eur. J. Biochem.</u> , 1997, 247:386-395			
	164	Gillis et al., "T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity," J. Immunol., 1978, 120(6):2027-2032			
	165	Gonzalez Lio and Thiem, "Chemoenzymatic synthesis of spacer-linked oligosaccharides for the preparation of neoglycoproteins," <u>Carbohydr. Res.</u> , 1999, 317:180-190			
٠	166	Solutions," Iransius. Sci., 1995, 16:5-17			
•	167	Grabenhorst et al., "Construction of stable BHK-21 cells coexpressing human secretory glycoproteins and human Gal(β1-4)GlcNAc-R α2,6-sialyltransferase: α2,6-Linked NeuAc is preferentially attached to the Gal(β1-4)GlcNAc(β1-2)Man(α1-3)-branch of diantennary oligosaccharides from secreted recombinant β-trace protein," Eur. J. Biochem., 1995, 232:718-725			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	ot in conformance and not considered. Include copy of this form with

Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 14503-010US1	Application No. 10/506,366
- · · · · · · · · · · · · · · · · · · ·	closure Statement	Applicant Michele Orlando et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date February 2, 2005	Group Art Unit 1623

	Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document		
	168	Grabenhorst and Conradt, "The Cytoplasmic, Transmembrane, and Stem Regions of Glycosyltransferases Specify Their <i>in vivo</i> Functional Sublocalization and Stability in the Golgi," <u>J. Biol. Chem.</u> , 1999, 274(51):36107-36116		
	169	Grabenhorst et al., "Biosynthesis and secretion of human interleukin 2 glycoprotein variants from baculovirus-infected Sf21 cells. Characterization of polypeptides and posttranslational modifications," Eur. J. Biochem., 1993, 215:189-197		
	170	Grabenhorst et al., "In Vivo Specificity of Human α 1,3/4-Fucosyltransferases III-VII in the Biosynthesis of Lewis" and Sialyl Lewis" Motifs on Complex-type N-Glycans. Coexpression studies from BHK-21 cells together with human β -trace protein," J. Biol. Chem., 1998, 273(47):30985-30994		
	171	Grabenhorst et al., "Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells," Glycoconj J., 1999, 16(2):81-97		
	172	Gray, "The Direct Coupling of Oligosaccharides to Proteins and Derivatized Gels," <u>Arch. Biochem.</u> Biophys., 1974, 163:426-428 (Fig. 2.1a)		
	173	Greenfield et al., "Evaluation in Vitro of Adriamycin Immunoconjugates Synthesized Using an Acid-sensitive Hydrazone Linker," Cancer Research, 1990, 50:6600-6607		
	174	Grimmecke and Brade, "Studies on the reductive amination of 3-deoxy-D-manno-octulosonic acid (Kdo)," Glycoconj. J., 1998, 15:555-562		
	175	Habeeb, "Determination of Free Amino Groups in Proteins by Trinitrobenzenesulfonic Acid," Anal. Biochem., 1966, 14:328-336		
	176	Subs., and Immob. Blotech., 1994, 22(3):923-931		
	177	Hallaway et al., "Modulation of Deferoxamine Toxicity and Clearance by Covalent Attachment to Biocompatible Polymers," Proc. Natl. Acad. Sci. USA, 1989, 86:10108-10112		
	178	2003, 14:320-330		
	179	Hartman and Wold, "Cross-Linking of Bovine Pancreative Ribonuclease A with Dimethyl Adipimidate," Biochemistry, 1967, 6(8):2439-2448		
	180	29:1271-1279		
	181	Hattori et al., "Reduced Immunogenicity of β-Lactoglobulin by Conjugation with Carboxymethyl Dextran," <u>Bioconjug. Chem.</u> , 2000, 11:84-93		
	182	Herman et al., "Characterization, Formulation, and Stability of Neupogen® (Filgrastim), a Recombinant Human Granulocyte-Colony Stimulating Factor," Formulation, Characterization, and Stability of Protein Drugs, Pearlman and Wang (eds.), Plenum Press, Chapter 7, 1996, pp. 303-328		
	183	Hermanson, Bioconjugate Techniques, 1996 (TOC only)		
	184	Hermentin et al., "A Strategy for the Mapping of N-Glycans by High-pH Anion-Exchange Chromatography with Pulsed Amperometric Detection," Anal. Biochem., 1992, 203(2):281-289		
	185	Higuchi et al., "Role of Sugar Chains in the Expression of the Biological Activity of Human Erythropoietin," J. Biol. Chem., 1992, 267(11):7703-7709		

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	it in conformance and not considered. Include copy of this form with
TO A COMMISSION TO SPENDEN	Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 14503-010US1	Application No. 10/506,366
1	closure Statement	Applicant Michele Orlando et al.	
(Use several sheets if necessary) (37 CER \$1 98(b))		Filing Date February 2, 2005	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Initial	Desig. ID	Document	
miliai	186	Sharaf et al., "Studies on Aroyl- and Aryl-Hydrazide Derivatives from D-glycero-D-gulo-Heptono-1,4- Lactone," Carbohydrate Res., 1981, 91:39-48	
	187	Inoue et al., "An Improved Method for the Purification of Human Erythropoietin with High in Vivo Activity from the Urine of Anemic Patients," Biol. Pharm. Bull., 1994, 17(2):180-184	
	188	Iwamoto et al., "Polysaccharide-Coated Oil Droplets in Oil-in-Water Emulsions as Targetable Carriers for Lipophilic Drugs," J. Pharm. Sci., 1991, 80(3):219-224	
	189	Jia et al., "S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control," Nature, 1996, 380:221-226	
	190	Jones et al., "A convenient synthesis of <i>N</i> -(<i>tert</i> -butyloxycarbonyl)aminooxy ethers," <u>Tetrahedron</u> Letters, 2000, 41(10):1531-1533	
	191	Jones et al., "Multivalent Poly(ethylene glycol)-Containing Conjugates for In Vivo Antibody Suppression," Bioconj. Chem., 2003, 14(6):1067-1076	
	192	Kallin, "Coupling of Oligosaccharides to Proteins Using <i>p</i> -Trifluoroacetamidoaniline," Meth. Enzymol., 1994, 242:119-123	
	193	Keaney, Jr. et al., "NO Forms an Adduct with Serum Albumin that Has Endothelium-derived Relaxing Factor-like Properties," J. Clin. Invest., 1993, 91:1582-1589	
	194	Keipert et al., "Functional properties of a new crosslinked hemoglobin designed for use as a red cell substitute," Transfusion, 1989, 29:768-773	
	195	Kitamura et al., "Establishment and Characterization of a Unique Human Cell Line That Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," J. Cell. Phys., 1989, 140:323-334	
,	196	Kitamura et al., "Chemical Engineering of the Monoclonal Antibody A7 by Polyethylene Glycol for Targeting Cancer Chemotherapy," Cancer Res., 1991, 51:4310-4315	
	197	Kleine-Tebbe et al., "Allergen Immunotherapy – A Position Paper of the German Society for Allergology and Clinical Immunology," Pneumologie, 2001, 55:438-444 (w/English summary)	
	198	Klemm et al., "Esterification of Cellulose," Comprehensive Cellulose Chemistry, 1998, Vol. 2, Wiley-VCH, Weinheim, New York, especially chapter 4.4, pps. 99-207	
	199	Kobayashi et al., "Reduced Immunogenicity of β-Lactoglobulin by Conjugation with Carboxymethyl Dextra Differing in Molecular Weight," J. Agric. Food Chem., 2001, 49(2):823-831	
	200	Kojima et al., "Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C," J. Pharm. Pharmacol., 1980, 32:30-34	
	201	Komatsu et al., "Cloning of granulocyte colony-stimulating factor cDNA from human macrophages and its expression in <i>Escherichia coli</i> ," Jpn. J. Cancer Res., 1987, 78(11):1179-1181	
	202		
	203	11(1):18-31	
•	204	Spleen Cells from Phenylhydrazine Treated Mice, Exp. Hematol., 1983, 11(7):049-000	
•	205	Krystal et al., "Purification of Human Erythropoietin to Homogeneity by a Rapid Five-Step Procedure," <u>Blood</u> , 1986, 67(1):71-79	
	206	Kuberan et al., "Preparation and isolation of neoglycoconjugates using biotin-streptavidin complexes," Glycoconj. J., 1999, 16:271-281	

	·			
Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with				
next communication to applicant.				

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-010US1	Application No. 10/506,366
	losure Statement plicant	Applicant Michele Orlando et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date February 2, 2005	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document Total Control		
	207	Kurtz and Eckardt, "Assays for Erythropoietin," Nephron., 1989, 51(suppl 1):11-14 (w/English summary)		
	208	Larionova et al., "Conjugation of the Bowman-Birk Soybean Proteinase Inhibitor with Hydroxyethylstarch," Appl. Biochem. Biotech., 1997, 62:175-182		
	209	Lee (ed.), "Synthesis of Peptides and Proteins," Peptide and Protein Drug Delivery, 1991, p. 65		
	210	Lee and Lee, "Neoglycoproteins," <u>Glycoproteins II</u> , 1997, Chapter 17, Elsevier Science B.V., pps. 301-620		
	211	Leenders et al., "β-Glucuronyl Carbamate Based Pro-moieties Designed for Prodrugs in ADEPT," <u>Tetrahedron Letters</u> , 1995, 36(10):1701-1704		
	212	Vaccine, 1996, 14(3):190-198		
	213	Lesnefsky et al., "High-Dose Iron-Chelator Therapy During Reperfusion with Deferoxamine-Hydroxyethyl Starch Conjugate Fails to Reduce Canine Infarct Size," <u>J. Cardiovasc. Pharmacol.</u> , 1990, 16(4):523-528		
	214	Levy et al., "Recombinant Antithrombin: Production and Role in Cardiovascular Disorder," <u>Sem. Thromb. Hem.</u> , 2001, 27(4):405-416		
	215	Lin et al., "Cloning and expression of the human erythropoietin gene," <u>Proc. Natl. Acad. Sci. USA</u> , 1985, 82:7580-7584		
	216	1 Systems, <u>1 etraneuron</u> , 1994, 50(50).6941-6906, especially p. 6950		
	217	Lomant and Fairbanks, "Chemical Probes of Extended Biological Structures: Synthesis and Properties of the Cleavable Protein Cross-linking Reagent [35S]Dithiobis(succinimidyl propionate)," J. Mol. Biol., 1976, 104:243-261		
	218	Lönngren and Goldstein, "Coupling of Aldobionic Acids to Proteins Using Water-Soluble Carbodiimide," Meth. Enzymol., 1994, 242:116-118		
	219	Manger et al., "1-N-Glycyl β-Oligosaccharide Derivatives as Stable Intermediates for the Formation of Glycoconjugate Probes," <u>Biochemistry</u> , 1992, 31:10724-10732		
	220	Manger et al., "Synthesis of 1-N-Glycyl β -Oligosaccharide Derivatives. Reactivity of Lens culinaris		
	221	Maout et al., "Hydroxyethylstarch Conjugated to Human Hemoglobin for use in Blood Transfusion: Comparison with Dextran Conjugates," <u>Carbohydrates and Carbohydrate Polymers - Analysis</u> , <u>Biotechnology, Modification</u> , <u>Antiviral and Other Applications</u> , 1993, Chapter 12, pp. 132-140		
	222	McMahon et al., "Pharmacokinetics and Effects of Recombinant Human Erythropoietin After Intravenous and Subcutaneous Injections in Healthy Volunteers," <u>Blood</u> , 1990, 76(9):1718-1722		
•	223	Meinjohanns et al., "Novel sequential solid-phase synthesis of N-linked glycopeptides from natural sources," J. Chem. Soc., Perkin Trans. 1, 1998, 1:549-560		
•	224	Mikola and Hänninen, "Introduction of Aliphatic Amino and Hydroxy Groups to Keto Steroids Using O-Substituted Hydroxylamines," Bioconj. Chem., 1992, 3(2):182-186		
	225	Minnema et al., "Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with <i>Escherichia coli</i> ," <u>Blood</u> , 2000, 95(4): 1117-1123		
Evaminar Sia		Data Considered		

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with
	Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 14503-010US1	Application No. 10/506,366
	losure Statement plicant	Applicant Michele Orlando et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date February 2, 2005	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.	,		
Initial	ID	Document		
	226			
	227	Montreuil et al., "Hexuronic acids," Carbohydrate analysis: a practical approach, 1996, Chaplin and		
	221	Kennedy (eds.), Chapter 5, pp. 175-204		
	228	Mosbech et al., "Hyposensitization in asthmatics with mPEG-modified and unmodified house dust		
	220	mite extract," Allergy, 1990, 45(2):130-141		
	229	Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to		
	229	Proliferation and Cytotoxicity Assays," J. Immunol. Meth., 1983, 65:55-63		
	220	Mueller et al., "Recombinant Glycoprotein Product Quality in Proliferation-Controlled BHK-21		
	230	Cells," Biotechnol. Bioeng., 1999, 65(5):529-536		
	221	Davis and Flitsch, "A Novel Method for the Specific Glycosylation of Proteins," Tetrahedron Lett.,		
	231	1991, 32(46):6793-6796		
	222	Nagata et al., "The chromosomal gene structure and two mRNAs for human granulocyte colony-		
	232	stimulating factor," EMBO J., 1986, 5(3):575-581		
	222	Nagata et al., "Molecular cloning and expression of cDNA for human granulocyte colony-		
	233	stimulating factor," Nature, 1986, 319:415-418		
		Nakane et al., "The Accumulation Mechanism of Cationic Mitomycin C-dextran Conjugates in the		
	234	l		
		Pharmacol., 1988, 40:1-6		
		Nedospasov and Khomutov, "Synthesis and some properties of aminooxyalkylcelluloses," Bulletin		
	235	of the Academy of Sciences of the USSR, 1976, Division of Chemical Science, Consultants Bureau,		
		New York, 25:1105-1110		
	226	Nimtz et al., "Structural characterization of the oligosaccharide chains of native and crystallized boar		
	236	seminal plasma spermadhesin PSP-I and PSP-II glycoforms," Eur. J. Biochem., 1999, 265:703-718		
	227	Nimtz et al., "Structures of sialylated oligosaccharides of human erythropoietin expressed in		
	237	recombinant BHK-21 cells," Eur. J. Biochem., 1993, 213:39-56		
	220	Nimtz et al., "Carbohydrate structures of a human tissue plasminogen activator variant expressed in		
	238	recombinant Chinese hamster ovary cells," FEBS Lett., 1990, 271:14-18		
		Nohynek et al., "Comparison of the potency of glycosylated and nonglycosylated recombinant		
	239	human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats," Cancer		
		<u>Chemother Pharmacol.</u> , 1997, 39:259-266		
	240	Nomura et al., "Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran		
	240	conjugates after intratumoural injection," J. Controlled Release, 1998, 52:239-252		
	241	O'Shannessy and Wilchek, "Immobilization of Glycoconjugates by Their Oligosaccharides: Use of		
	241	Hydrazido-Derivatized Matrices," Analytical Biochemistry, 1990, 191:1		
		Pawlowski et al., "A new method of non-cross-linking conjugates of polysaccharides to protein via		
	242	thioether bonds for the preparation of saccharide-protein conjugate vaccines," Vaccine, 1999,		
		17:1474-1483		
	243	Pazur, "Neutral polysaccharides," Carbohydrate analysis: a practical approach, 1996, Chaplin and		
	243	Kennedy (eds.), Chapter 3, pp. 55-96		
•	244	Pedley et al., "The potential for enhanced tumour localization by poly)ethylene glycol) modification		
	244	of anti-CEA antibody," Br. J. Cancer, 1994, 70:1126-1130		

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	at in conformance and not considered. Include conv of this form with
	it in comormatice and not considered, include copy of this form with
next communication to applicant.	
	Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 14503-010US1	Application No. 10/506,366
	closure Statement	Applicant Michele Orlando et al.	
(Use several sheets if necessary) (37 CER \$1 98(b))		Filing Date February 2, 2005	Group Art Unit 1623

Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.	Dogument	
Initial	245	Peeters et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <u>J. Immunol. Meth.</u> , 1989, 120:133-143	
	246	Peron et al., "Hydroxyethyl starch-induced renal insufficiency after plasma exchange in a patient with polymyositis and liver cirrhosis," Clin. Nephrol., 2001, 55(5):408-411	
	247	Pharma Business, July/August 2000, pages 45-60	
	248	Quelle et al., "High-Level Expression and Purification of a Recombinant Human Erythropoietin Produced Using a Baculovirus Vector," <u>Blood</u> , 1989, 74(2):652-657	
	249	Rabiner et al., "Evaluation of a stroma-free hemoglobin solution for use as a plasma expander," <u>J. Exp. Med.</u> , 1967, 126:1127-1142	
	250	Ragupathi et al., "A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm," Glycoconj. J., 1998, 15:217-221	
	251	Ramos et al., "Enzymatic Synthesis of Neoglycopeptide Building Blocks," Angew. Chem. Int. Ed., 2000, 39(2):396-398	
	252	Reidhaar-Olson et al., "Identification of Residues Critical to the Activity of Human Granulocyte Colony-Stimulating Factor," <u>Biochemistry</u> , 1996, 35:9034-9041	
	253	Relihan et al., "Clearance Rate and Effect on Renal Function of Stroma-Free Hemoglobin Following Renal Ischemia," Ann. Surg., 1972, 176(6):700-704	
	254	Richter and de Belder, "Antibodies against Hydroxyethylstarch Produced in Rabbits by Immunization with a Protein-Hydroxyethylstarch Conjugate," Int. Arch. Allergy Appl. Immun.," 1976, 52:307-314	
	255	Rogers et al., "Effects of polymerization on the oxygen carrying and redox properties of diaspirin cross-linked hemoglobin," <u>Biochim. Biophys. Acta</u> , 1995, 1248:135-142	
	256	Rohrling et al., "Synthesis and testing of a novel fluorescene label for carbonyls in carbohydrates and cellulosics," Synlett, 2001, 5:682-684	
	257	Rose, "Facile Synthesis of Homogeneous Artificial Proteins," J. Am. Chem. Soc., 1994, 116:30-33	
	258	Rudolph et al., "Circulation persistence and biodistribution of lyophilized liposome-encapsulated hemoglobin: An oxygen-carrying resuscitative fluid," Crit. Care Med., 1994, 22:142-150	
	259	Rudolph, "The Freeze-Dried Preservation of Liposome Encapsulated Hemoglobin: A Potential Blood Substitute," Cryobiology, 1988, 25:277-284	
	260	Rush et al., "Microheterogeneity of Erythropoietin Carbohydrate Structure," Anal. Chem., 1995, 67(8):1442-1452	
	261	(200/0.5) and normal saline on coagulation, Br. J. Anaestnesia, 1996, 60(3):012-010	
•	262	Sadamoto et al., "Control of Bacteria Adhesion by Cell-Wall Engineering," J. Am. Chem. Soc., 2004, 126:3755-3761	
•	263	Sadrzadeh et al., "The Long-Acting Parenteral Iron Chelator, Hydroxyethyl Starch-Deferoxamine, Fails to Protect Against Alcohol-Induced Liver Injury in Rats," <u>J. Pharmacol. Exp. Ther.</u> , 1997, 280(2):1038-1042	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	ot in conformance and not considered. Include copy of this form with

Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 14503-010US1	Application No. 10/506,366
	losure Statement plicant	Applicant Michele Orlando et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date February 2, 2005	Group Art Unit 1623

	Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner	Desig.		
Initial	ID	Document	
	264	Sakai et al., "Synthesis and Physicochemical Characterization of a Series of Hemoglobin-Based Oxygen Carriers: Objective Comparison between Cellular and Acellular Types," <u>Bioconj. Chem.</u> , 2000, 11:56-64	
	265	Sato et al., "Disposition of a Polymeric Prodrug of Mitomycin C, Mitomycin C-Dextran Conjugate, in the Perfused Rat Liver," J. Pharm. Sci., 1989, 78:11-16	
	266	Sawaikar et al., "Products active on mosquitoes. Part VII, Synthesis and biological activity of longifolene derivatives," <u>Indian Journal of Chemistry</u> , 1995, 34B:832-835	
	267	Scaglione et al., "A New Model Examining Intracellular and Extracellular Activity of Amoxicillin, Azithromycin, and Clarithromycin in Infected Cells," Chemotherapie, 1993, 39:416-423	
	268	Schäfer et al., "Two-year double-blind trial of a monomethoxy polyethylene glycol (mPEG) modified grass pollen extract at different dose levels," Ann. Allergy, 1992, 68(4):334-339	
	269	Schlenke et al., "Construction and characterization of stably transfected BHK-21 cells with human-type sialylation characteristic," Cytotechnology , 1999, 30:17-25	
	270	Schottelius et al., "Improvement of Pharmacokinetics of Radioiodinated Tyr ³ -Octreotide by Conjugation with Carbohydrates," <u>Bioconjugate Chem.</u> , 2002, 13:1021-1030	
	271	Schröter et al., "Male-specific Modification of Human CD52," J. Biol. Chem., 1999, 274(42):29862-29873	
	272	Shafer et al., "Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides," <u>Vaccine</u> , 2000, 18:1273-1281	
	273	Shah et al., "Characterization of Colony-stimulating Activity Produced by Human Monocytes and Phytohemagglutinin-stimulated Lymphocytes," 1977, <u>Blood</u> , 50(5):811-821	
	274	Shirafuji et al., "A new bioassay for human granulocyte colony-stimulating factor (hG-CSF) using murine myeloblastic NFS-60 cells as targets and estimation of its levels in sera from normal healthy persons and patients with infectious and hematological disorders," Exp. Hematol., 1989, 17:116-119	
	275	Simmons et al., "Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist," Science, 1997, 276:276-279	
	276	Snyder et al., "HbXL99α A hemoglobin derivative that is cross-linked between the α subunits is useful as a blood substitute," Proc. Natl. Acad. Sci. USA, 1987, 84:7280-7284	
	277	Shu, "Somogyi Micro Copper Method," Method in Carbohydride Chemistry, 1962, 1:383-388	
	278	Song et al., "Toxicity and Antitumor Activity of the Conjugate of Mitomycin C with Carboxymethyl-chitin," Arch. Pract. Pharm., 1993, 53(3):141-147	
	279	Souza et al., "Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells," Science, 1986, 232:61-65	
•	280	Soyez et al., "Biological evaluation of mitomycin C bound to a biodegradable polymeric carrier," <u>J. Controlled Release</u> , 1997, 47:71-80	
	281	Spivak and Hogans, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat," Blood, 1989, 73:90-99	
•	282	Staros, "N-Hydroxysulfosuccinimide Active Esters: Bis(N-hydroxysulfosuccinimide) Esters of Two Dicarboxylic Acids Are Hydrophilic, Membrane-Impermeant, Protein Cross-Linkers," <u>Biochemistry</u> , 1982, 21:3950-3955	

Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with				
next communication to applicant.				

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-010US1	Application No. 10/506,366
	losure Statement plicant	Applicant Michele Orlando et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date February 2, 2005	Group Art Unit 1623

	Other Do	ocuments (include Author, Title, Date, and Place of Publication)	
Examiner Initial	Desig. ID	Document	
IIIIIIai	283	Sunamoto and Iwamoto, "Protein-Coated and Polysaccharide-Coated Liposomes as Drug Carriers,"	
	283	CRC Critical Review in Therapeutic Drug Carrier Systems, 1986, 2:117-136	
	284	Sytkowski et al., "Human erythropoietin dimers with markedly enhanced in vivo activity," Proc. Natl. Acad. Sci. USA, 1998, 95(3):1184-1188	
·	285	Sytkowski et al., "An Erythropoietin Fusion Protein Comprised of Identical Repeating Domains Exhibits Enhanced Biological Properties," J. Biol. Chem., 1999, 274(35):24773-24778	
	286	86:7819-7822	
	287	Takeuchi and Kobata, "Structures and functional roles of the sugar chains of human erythropoietins," Glycobiology, 1991, 1(4):337-346	
	288	Tam et al., "Soluble Dextran-Hemoglobin Complex as a Potential Blood Substitute," <u>Proc. Natl.</u> Acad. Sci. USA, 1976, 73(6):2128-2131	
	289	Tanaka et al., "Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats," <u>Cancer Research</u> , 1991, 51:3710-3714	
	290	Thomas et al., "Measuring blood volume with fluorescent-labeled hydroxyethyl starch," Crit. Care Med., 2000, 28(3):627-631	
	291	Thomas, "Carbohydrate Binding Sites," Meth. Enzymol., 1977, 46:362-368	
	292	Thorpe et al., "Blockade of the galactose-binding sites of ricin by its linkage to antibody," <u>Eur. J. Biochem.</u> , 1984, 140:63-71	
	293	Toyama et al., "Surface design of SPR-based immunosensor for the effective binding of antigen or antibody in the evanescent field using mixed polymer matrix," Sensors and Actuators B, 1998, 52:65-71	
	294	De Velasco et al., "Synthetic Peptides Representing T-Cell Epitopes Act as Carriers in Pneumococcal Polysaccharide Conjugate Vaccines," Infect. Immun., 1995, 63(3):961-968	
	295	Van Patten et al., "Oxidation of Methionine Residues in Antithrombin," <u>J. Biol. Chem.</u> , 1999, 274(15):10268-10276	
	296	Appl. Biochem. Biotech., 1985, 11:141-152	
	297	Vilaseca et al., "Protein conjugates of defined structure: Synthesis and use of a new carrier molecule," Bioconjugate Chemistry, 1993, 4(6):515-520	
	298	Reagents," Bioconjugate Chem., 1990, 1:96-99	
•	299	Weidler et al., "Pharmakokinetische Merkmale als Kriterien für den klinischen Einsatz von Hydroxyethylstärke," <u>ArzneimForsch./Drug Res.</u> , 1991, 41:494-498 (w/English summary)	
	300	White and Kennedy, "Oligosaccharides," <u>Carbohydrate analysis: a practical approach</u> , 1996, Chaplin and Kennedy (eds.), Chapter 2, pp. 1-36	
•	301	Whitesides et al., "Rates of Thiol-Disulfide Interchange Reactions between Mono- and Dithiols and Ellman's Reagent," <u>J. Org. Chem.</u> , 1977, 42(2):332-338	
	302	Wong et al., "Analysis of carbohydrate-protein interactions with synthetic N-linked neoglycoconjugate probes," Biochem. J., 1993, 296:817-825	

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14503-010US1	Application No. 10/506,366
	losure Statement plicant	Applicant Michele Orlando et al.	
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date February 2, 2005	Group Art Unit 1623

(Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig.	Document	
·	303	Wong et al., "Synthetic glycosylation of proteins using N-(β-saccharide) iodoacetamides: applications in site-specific glycosylation and solid-phase enzymic oligosaccharide synthesis," Biochem. J., 1994, 300:843-850	
	304	Wong, Chemistry of protein conjugation and cross-linking, 1993, CRCS, Inc. (TOC only)	
	305	Xue and Wong; "Preparation of Conjugated Hemoglobins," Meth. Enzymol., 1994, 231:308-322	
	306	Yalpani et al., "Selective Chemical Modifications of Dextran," <u>J. Polymer Science: Polymer Chemistry Edition</u> , 1985, 23:1395-1405	
	307	Yamaguchi et al., "Effects of site-directed removal of N-glycosylation sites in human erythropoietin on its production and biological properties," J. Biol. Chem., 1991, 266(30):20434-20439	
	308	Yoshida, "Glycamine Formation via Reductive Amination of Oligosaccharides with Benzylamine," Meth. Enzymol., 1994, 247:55-64	
	309	Zalipsky, "Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevant Conjugates," Bioconjugate Chem., 1995, 6:150-165	
	310	Zara et al., "A Carbohydrate-Directed Heterobifunctional Cross-Linking Reagent for the Synthesis of Immunoconjugates," Anal. Biochem., 1991, 194:156-162	
	311	Zettlmeissl et al., "Characterization of Recombinant Human Antithrombin III Synthesized in Chinese Hamster Ovary Cells," J. Biol. Chem., 1989, 264 (35):21153-21159	
	312	Zhou et al., "Application of capillary electrophoresis, liquid chromatography, electrospray-mass spectrometry and matrix-assisted laserdesorption/ionization - time of flight - mass spectrometry to the characterization of recombinant human erythropoietin," <u>Electrophoresis</u> , 1998, 19(13):2348-2355	
	313	515	
	314	Zucali and Sulkowski, "Purification of human urinary erythropoietin on controlled-pore glass and silicic acid," Exp. Hematol., 1985, 13(3):833-837	

Examiner Signature	Date Considered	
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		